Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Binimetinib, and Bevacizumab in Refractory Colorectal Cancer
NCT03475004Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Sep 2018
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, binimetinib, bevacizumab in colorectal cancer (CRC), sponsored by University of Colorado Denver. Started Sep 2018; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03475004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03475004.